Azitra, Inc. (AZTR)
- Business Wire
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
BRANFORD, Conn., May 31, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center.
- Business Wire
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
BRANFORD, Conn., May 17, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline. The data are being presented on Friday, May 17, 2024, in two oral sessions entitled "Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity" and "Cutaneous delivery of LE
- Business Wire
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
BRANFORD, Conn., May 10, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline. The data are being presented on Friday, May 10, 2024, in two oral sessions entitled "Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases" and "Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR12
